CONTENTS:
• The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. Dunn K.E., Sigmon S.C., Strain E.C., Heil S.H., Higgins S.T., p. 1-9.
• Could a continuous measure of individual transmissible risk be useful in clinical assessment of substance use disorder? Findings from the National Epidemiological Survey on Alcohol and Related Conditions. Ridenour T.A., Kirisci L., Tarter R.E., Vanyukov M.M., p. 10-17.
• Maternal risk factors predicting child physical characteristics and dysmorphology in fetal alcohol syndrome and partial fetal alcohol syndrome. May P.A., Tabachnick B.G., Gossage J.P., Kalberg W.O., Marais A.S., Robinson L.K., et al., p. 18-27.
• Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Martins S.S., Gorelick D.A., p. 28-36.
• A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram. Roache J.D., Kahn R., Newton T.F., Wallace C.L., Murff W.L., De La Garza R., 2nd, et al., p. 37-45.
• Effects of stress and alcohol cues in men with and without problem gambling and alcohol use disorder. Steinberg L., Tremblay A.M., Zack M., Busto U.E., Zawertailo L.A., p. 46-55.
• Clinician and service user perceptions of implementing contingency management: A focus group study. Sinclair J.M., Burton A., Ashcroft R., Priebe S., p. 56-63.
• Treatment of adolescents with a cannabis use disorder: Main findings of a randomized controlled trial comparing multidimensional family therapy and cognitive behavioral therapy in The Netherlands. Hendriks V., van der Schee E., Blanken P., p. 64-71.
• Mindfulness training for smoking cessation: Results from a randomized controlled trial. Brewer J.A., Mallik S., Babuscio T.A., Nich C., Johnson H.E., Deleone C.M., et al., p. 72-80.
• Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder. Nunes F., Ferreira-Rosa K., Pereira Mdos S., Kubrusly R.C., Manhaes A.C., Abreu-Villaca Y., et al., p. 81-87.
• Methadone maintenance and cancer risk: An Israeli case registry study. Grinshpoon A., Barchana M., Lipshitz I., Rosca P., Weizman A., Ponizovsky A.M., p. 88-92.
• Prolonged use of benzodiazepines is associated with childhood trauma in opioid-maintained patients. Vogel M., Dursteler-Macfarland K.M., Walter M., Strasser J., Fehr S., Prieto L., et al., p. 93-98.
• Benzodiazepine dependence among multidrug users in the club scene. Kurtz S.P., Surratt H.L., Levi-Minzi M.A., Mooss A., p. 99-105.
• Suicide attempts and overdoses among adults entering addictions treatment: Comparing correlates in a U.S. national study. Bohnert A.S., Roeder K.M., Ilgen M.A., p. 106-112.
• Endothelial dysfunction during acute alcohol withdrawal syndrome. Jochum T., Weissenfels M., Seeck A., Schulz S., Boettger M.K., Voss A., et al., p. 113-122.
• The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress. Allsop D.J., Norberg M.M., Copeland J., Fu S., Budney A.J., p. 123-129.
• Using NicAlert strips to verify smoking status among pregnant cigarette smokers. Gaalema D.E., Higgins S.T., Bradstreet M.P., Heil S.H., Bernstein I.M., p. 130-133.
• Injection methamphetamine use is associated with an increased risk of attempted suicide: A prospective cohort study. Marshall B.D., Galea S., Wood E., Kerr T., p. 134-137.
• Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study. Brodish P., Singh K., Rinyuri A., Njeru C., Kingola N., Mureithi P., et al., p. 138-141.
• Integrating field methodology and web-based data collection to assess the reliability of the Alcohol Use Disorders Identification Test (AUDIT). Celio M.A., Vetter-O'Hagen C.S., Lisman S.A., Johansen G.E., Spear L.P., p. 142-144.
• Prevalence, characteristics, and predictors of police training initiatives by US SEPs: Building an evidence base for structural interventions. Beletsky L., Grau L.E., White E., Bowman S., Heimer R., p. 145-149.
ONLINE ARTICLES:
• When drugs in the same controlled substance schedule differ in real-world abuse, should they be differentiated in labeling? Dasgupta N., Henningfield J.E., Ertischek M.D., Schnoll S.H., p. e1-4.
• Ability of baclofen to prevent somatic manifestations and neurochemical changes during nicotine withdrawal. Varani A.P., Moutinho L.M., Calvo M., Balerio G.N., p. e5-e12.
• Cultural competence in outpatient substance abuse treatment: Measurement and relationship to wait time and retention. Guerrero E., Andrews C.M., p. e13-22.
• A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Bisaga A., Sullivan M.A., Cheng W.Y., Carpenter K.M., Mariani J.J., Levin F.R., et al., p. e23-29.